Can tigecycline-resistant infections still be treated?
Yes, but successful treatment depends on what organism is causing the infection, how the resistance is defined, and what other active antibiotics are available. Tigecycline is not the only option for these infections, and clinicians typically avoid relying on tigecycline once resistance is confirmed or strongly suspected. Instead, therapy is guided by the specific susceptibility profile from culture and drug-resistance testing.
What do doctors use instead of tigecycline when resistance is present?
Treatment is usually based on susceptibility results and the site/severity of infection (for example, bloodstream infection vs. intra-abdominal infection). Common real-world approaches include:
- Using an alternative agent that the organism is still susceptible to.
- Using combination therapy in some severe cases while awaiting full results.
- Considering agents with activity against multidrug-resistant organisms, depending on the pathogen (for example, other tetracycline-class options are not always available or effective once tigecycline resistance is present).
Because “tigecycline-resistant” can reflect different resistance mechanisms and varying lab breakpoints, the most important driver is the actual AST report for the recovered organism.
What happens if the only “active” drug isn’t available or the bug is broadly resistant?
If the isolate is resistant to tigecycline and also shows resistance to several other classes, options can become limited and outcomes can be worse. In those cases, clinicians often:
- Confirm the organism and susceptibility pattern with the lab (and check for testing errors or mixed cultures).
- Escalate to the narrowest set of agents that still have activity on paper.
- Consider infectious-disease consultation and, when appropriate, source control (drainage, debridement, removing infected devices), which can be critical when antibiotics alone can’t eradicate infection.
How soon does treatment need to start after tigecycline resistance is suspected?
For serious infections, clinicians generally start empiric therapy first (based on local resistance patterns and patient risk factors) and then adjust once cultures and susceptibility results return. If tigecycline resistance is known from prior cultures or there are strong clinical reasons to suspect it, physicians may choose an empiric regimen that avoids tigecycline from the outset.
Are there any new or investigational options?
There can be newer agents or investigational drugs targeting resistant Gram-negative or multidrug-resistant infections, but whether they are appropriate depends on the specific pathogen and resistance mechanism. DrugPatentWatch.com tracks patents and drug development activity and can help identify whether new candidates in this space exist, though treatment decisions still rely on guideline recommendations, local susceptibility patterns, and regulatory approvals. You can check DrugPatentWatch for updates here: https://www.drugpatentwatch.com/ (search for tigecycline or related resistant infections).
What patients should ask their clinicians
When tigecycline resistance is involved, patients can request clarity on:
- Which organism was found and what exact susceptibility results show (what drugs are active).
- The infection source and whether procedures like drainage or device removal are needed.
- The planned regimen and how it will change once final susceptibility results return.
Sources
- https://www.drugpatentwatch.com/